Cyxone enters into co-operation agreement with University of Queensland
Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.
Cyxone has signed an agreement with the University of Queensland to study how "therapeutic dosing" with T20K can inhibit the development of fresh MS symptoms in treated animals. The programme will seek to identify the conditions for early treatment with T20K in humans, and is included in the documentation that forms the basis for further studies in humans.
The co-operation agreement covers several studies in 2017, and has a total budget of approximately SEK 1 million.
The research group at the University of Queensland has extensive experience of studies in the MS-mice model, and the work will be followed-up on site by Dr. Christian Gruber, who heads Cyxone's scientific board.
Through the co-operation agreement with the University of Queensland, we feel confident of achieving high quality results with T20K for Cyxone's continued development.
For more information, please contact:
Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
211 22 Malmö
This information is information which Cyxone AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person, for publication on June 7, 2017.
About Cyxone Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.